 Bio-Path Holdings, Inc., BPTH, a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces the presentation of a poster highlighting the clinical trial design of its Phase 2 study of BP1001 prexigebersen at the 2020 American Society of Clinical Oncology ASCO Annual Meeting, taking place virtually from May 29-31, 2020. The poster, titled, A Phase II Study of BP1001 liposomal Grb2 antisense oligonucleotide in Patients with Hematologic Malignancies, was presented virtually by Dr. Maro Ohanian, Department of Leukemia, University of Texas M.D. Anderson Cancer Center. The poster describes the Phase 2 study design of BP1001 liposomal Grb2 antisense, the Companys lead drug candidate, in combination with decitabine as a potential treatment for patients diagnosed with acute myeloid leukemia AML or high-risk myelodysplastic syndrome MDS. 